All articles tagged with #personalized therapy
A JAMA Psychiatry study analyzing brain scans and neurochemical data from hundreds of children with ADHD identifies three distinct neuroclinical profiles—severe-combined with emotional dysregulation, predominantly hyperactive/impulsive, and predominantly inattentive—suggesting ADHD isn’t a single disorder and could lead to tailored treatments in the future.
A man with severe, treatment-resistant depression experienced joy for the first time in decades after a personalized brain stimulation treatment targeting specific brain networks, leading to sustained remission for two years. The approach involves precise electrode implantation and adjustable stimulation based on patient feedback, representing a promising advancement in psychiatric treatment.
Scientists used CRISPR-based base editing delivered via lipid nanoparticles to successfully treat a baby with a rare genetic metabolic disorder, marking a significant advancement in personalized gene therapy.
After losing his wife to colon cancer, New York tech entrepreneur Roy de Souza has dedicated himself to fighting the disease by founding BreakBio, a company focused on developing personalized cancer therapies using AI technology. Inspired by his wife's battle, de Souza aims to create targeted treatments tailored to each patient's unique disease, starting with colorectal cancer. While personalized cancer vaccines show promise, they also present challenges such as manufacturing complexity and limitations in immune response. Despite these obstacles, de Souza remains optimistic about the potential of AI-based approaches to revolutionize cancer treatment and make a meaningful impact in the fight against the disease.
Brain signals can be used to detect the severity of chronic pain, potentially leading to the development of personalized therapies for individuals suffering from severe pain conditions. Researchers from the University of California, San Francisco, implanted electrodes in the brains of four people with chronic pain and identified biomarkers of chronic pain in the brain signal patterns, which were as unique to the individual as a fingerprint. They used machine learning to model the results of the surveys and successfully predicted how the patients would score the severity of their pain by examining their brain activity.
A new study has found that chronic pain has a distinct brain activity pattern that is different from acute pain, suggesting there may be an identifiable brain "signature" for chronic pain. The research could lead to new treatment approaches and personalized therapies for the one in five Americans who suffer from chronic pain. The study's authors hope to add more patients to better understand the diversity of pain signatures and treatment targets.
Florida-based medical tech firm ArteraAI has developed the ArteraAI Prostate Test, the first predictive test for patients with localized prostate cancer. The test uses AI to analyze a biopsy of the cancerous tumor and certain clinical data to predict the likely outcomes for the patient and help the physician determine the optimal therapy. The test offers fast turnaround times and complements healthcare providers' work. While AI shows promise in healthcare, there is a need to protect patients' privacy and security and ensure the data represents the entire population it's intended to treat.